Ertapenem Once a Day Versus Piperacillin–Tazobactam Every6 Hours for Treatment of Acute Pelvic Infections:A Prospective, Multicenter, Randomized, Double-Blind Study

[摘要] Objective:To compare ertapenem therapy with piperacillin–tazobactam therapy for the management of acutepelvic infections.Methods:In a multicenter, double-blind study, 412 women with acute pelvic infection were assigned to one oftwo strata, namely obstetric/postpartum infection or gynecologic/postoperative infection, and were thenrandomized to ertapenem, 1 g once a day, or piperacillin–tazobactam, 3.375 g every 6 hours, both administeredintravenously.Results:In total, 163 patients in the ertapenem group and 153 patients in the piperacillin–tazobactam group wereclinically evaluable. The median duration of therapy was 4.0 days in both treatment groups. The most commonsingle pathogen wasEscherichia coli. At the primary efficacy endpoint 2–4 weeks post therapy, 93.9% of patientswho received ertapenem and 91.5% of those who received piperacillin–tazobactam were cured (95%confidence interval for the difference, adjusting for strata, –4% to 8.8%), indicating that cure rates for bothtreatment groups were equivalent. Cure rates for both treatment groups were also similar when compared bystratum and severity of infection. The frequency and severity of drug-related adverse events were generallysimilar in both groups.Conclusions:In this study, ertapenem was as effective as piperacillin–tazobactam for the treatment of acute pelvicinfection, was generally well tolerated, and had an overall safety profile similar to that of piperacillin–tazobactam.

[学科分类] 妇产科学